CD274 and non-small cell lung carcinoma: Interestingly, BrM patients with PD-L1 expression > 50% had both numerically better PFS and OS compared with those with PD-L1 expression ≤ 50%, suggesting PD-L1 expression may have potential impact on the efficacy of ICIs treatment in advanced NSCLC with BrMs.